[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Military University Hospital, Prague\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100625617","hepatic-venous-pressure-gradient-versus-endoscopic-ultrasound-guided-portal-pressure-gradient---comparative-analysis-hepca-100625617",false,"NCT07424963","Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA)","Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis","HEPCA","Inclusion Criteria:\n\n* Age 18-75 years at the time of enrollment; signed informed consent\n* Clinical indication for HVPG measurement and\u002For transjugular liver biopsy for chronic advanced liver disease\n\nExclusion Criteria:\n\n* Severe co-morbidities (e.g., advanced chronic heart failure, chronic renal insufficiency stage 4 and above, long-term poorly compensated diabetes mellitus with severe complications)\n* Pregnancy\n* Estimated patient non-compliance and\u002For not signing of the informed consent\n* Documented iodine contrast dye allergy\n* Presence of portal vein thrombosis or cavernomatous transformation of portal vein or hepatic vein obstruction\n* Ascites Grade 3\n* Biliary obstruction\n* Anticoagulation or antiplatelet therapy, which cannot be discontinued\n* INR \\> 1.5 and\u002For platelet count \\\u003C 50,000\u002Fµl\n* Hepatocellular carcinoma in the left lobe of the liver\n* Surgically altered upper gastrointestinal tract anatomy\n* State after transjugular intrahepatic portosystemic shunt\n* State after liver transplantation","ALL","18 Years","75 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this interventional trial is to compare in measuring of portal hypertension by HVPG and EUS-PPG in subject indicated to HVPG measurement.\n\nThe primary question is whether EUS-PPG provides measurements really equivalent to HVPG in terms of gradient accuracy.\n\nParticipants undergoing HVPG will first undergo the procedure while conscious, performed by the first operator. Immediately thereafter, HVPG will be repeated following the induction of anesthesia by a second operator blinded to the initial readings. Subsequently, EUS-PPG will be performed by an endoscopist, who will also be blinded to all previous pressure measurements.",[28,29,30,31,32,33],"Cirrhosis","Portal Hypertension","EUS","Non-Cirrhotic Portal Hypertension","HVPG","Hepatic Venous Pressure Gradient",[32,35,36,37],"EUS-PPG","portal hypertension","liver cirrhosis","RECRUITING","2026-02-16",{"date":41,"type":42},"2026-02-20","ACTUAL",{"date":44,"type":42},"2025-05-30",{"date":46,"type":22},"2028-12-31",{"name":48,"class":49},"Military University Hospital, Prague","OTHER",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100499291","stretta-versus-conservative-treatment-100499291","NCT05781347","Stretta Versus Conservative Treatment","Endoscopic Treatment of Gastro-esophageal Reflux Disease with Application of Radiofrequency Energy to the Lower Esophageal Sphincter (Stretta) Versus Conservative Treatment, Prospective Randomized Study","Inclusion Criteria:\n\nVerified symptomatic GERD despite PPI use, with persistent symptoms, desire to discontinue PPIs, or intolerance to them.\n\nPathological gastroesophageal reflux confirmed by positive 24-hour pH-metry with impedance.\n\nNormal findings on high-resolution esophageal manometry (HRM) according to CCv4.0.\n\nAge ≥ 18 years. Signed informed consent for participation in the trial and invasive procedures.\n\nExclusion Criteria:\n\nActive severe reflux esophagitis (Los Angeles classification grade C or D). Barrett's esophagus. Esophageal peptic stricture or eosinophilic esophagitis. Hiatal hernia ≥ 2 cm. Malignancies. Abnormal findings on high-resolution esophageal manometry. Esophageal or subcardial varices. Pregnancy. Severe comorbidities or increased perioperative risk. Age \\> 70 years due to increased perioperative risk and common comorbidities. Symptoms primarily attributable to functional dyspepsia, significant anxiety, or depression, with overlap to other disorders of gut-brain interaction (DGBI).","70 Years",{"count":60,"type":22},50,[25],"Gastroesophageal reflux disease (GERD) is one of the most common diseases of the gastrointestinal tract. Obesity is a significant risk factor for GERD; however, treatment outcomes in obese patients remain challenging. In the Czech Republic, therapeutic options are currently limited to conservative treatment, including pharmacotherapy and lifestyle modifications, or surgical interventions, both of which have known limitations. Stretta is a minimally invasive endoscopic therapy using radiofrequency energy delivered to the esophagogastric junction (EGJ) and cardia, aimed at enhancing the antireflux barrier.\n\nThis study evaluates the effectiveness and safety of the Stretta procedure compared to conservative treatment in managing GERD. Initially designed to compare outcomes between obese and non-obese populations, the study was expanded to include all GERD patients due to recruitment challenges and the need to meet strict eligibility criteria. These criteria ensure reliable results by focusing on patients with confirmed pathological GERD while excluding those with hiatal hernias ≥ 2 cm, severe esophagitis, or functional esophageal disorders such as hypersensitivity. The study aims to provide comprehensive data on the use of Stretta in the Czech Republic and its role in GERD management.",[64],"GERD","2025-01-05",{"date":67,"type":42},"2025-01-07",{"date":69,"type":42},"2022-09-01",{"date":71,"type":22},"2026-03-31",{"name":48,"class":49},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":73},"100510663","innovative-approach-to-detect-recurrent-colorectal-lesions-with-surveillance-via-mutation-analysis--clinical-phenotype-100510663","NCT05929365","Innovative Approach to Detect Recurrent Colorectal Lesions With Surveillance Via Mutation Analysis & Clinical Phenotype","Development and Clinical Utility of a New Method to Identify Patients With Risk of Recurrent Colorectal Lesions and Personalization of Their Surveillance Based on Mutation Burden and Clinical-pathological Phenotype","MTG","Inclusion Criteria:\n\n* Colorectal polyp larger than 10mm removed by colonoscopy therapeutic method (EPE, EMR, ESD)\n* Signed informed consent with the study and with colonoscopy\n\nExclusion Criteria:\n\n* FAP, HNPCC and other hereditary CRC syndromes probands\n* Colonoscopy contraindication\n* Severe acute inflammatory bowel disease\n* Severe comorbidities; likely non-compliance of the patient",true,{"count":84,"type":22},200,"5 Years","OBSERVATIONAL","It is known that the development of colorectal adenoma is dependent on the appearance of somatic mutations in protooncogenes and tumor suppressor genes. Based on our previous mutation analyses of 120 patients with high-risk adenoma removed by enbloc resection with subsequent colonoscopy after 1 year, there is a correlation between mutation in exon 7 of the TP53 gene and risk of early metachronous lesions development. The results also indicate that mutation phenotype (mutation profile and burden) of all lesions detected on index colonoscopy can determine risk of metachronous lesions. As not all synchronous lesions were analyzed and the surveillance colonoscopy interval was less than 3 years, this assumption could not be confirmed. In this study it is planned to perform mutation analysis of all synchronous lesions in 200 patients and correlate the data with appearance of metachronous lesions after 1, 3 and 5 years. Moreover, the mutation profile of all metachronous lesions developed during the 5 years of surveillance will be determinated and compared with mutation profile of index lesions from the same localization to verify their common biological origin. This all could help personalize the surveillance program in terms of reduction of the burden on the patient and endoscopic workplaces and risk of developing colorectal cancer in a particular patient.",[89],"Predictive Cancer Model",[91,92,93,94,95,96],"phenotype","surveillance","colonoscopy","colorectal neoplasia","genetic mutation","metachronous lesions","2023-06-25",{"date":99,"type":42},"2023-07-03",{"date":101,"type":42},"2022-05-01",{"date":103,"type":22},"2026-12-31",{"name":48,"class":49},""]